If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Are there safety or efficacy differences between Zepbound® (tirzepatide) injections in the abdomen versus thigh versus upper arm?
Similar exposure to tirzepatide was achieved after subcutaneous injection in the abdomen, thigh, or upper arm. There is no data from studies comparing these injection sites to assess efficacy and safety differences.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide should be injected under the skin (subcutaneously) of the stomach (abdomen), thigh, or upper arm.1
During studies, similar amounts of tirzepatide were found in the body after subcutaneous injection in the abdomen, thigh, or upper arm.1
Eli Lilly and Company cannot comment on safety and efficacy differences when using one approved injection site versus another because this has not been studied.
Patients should consult with their health care providers if they have questions about which of the approved injection site(s) is best. Health care providers may consider the patient's individual factors and medical history.
Enclosed Prescribing Information
Reference
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: December 19, 2024